hims hers glp 1 & Health shares surge as Novo Nordisk drops GLP-1 lawsuit Atlanta VA joins clinical 30 Day supply:1 Box collection_bundles

hims hers glp 1 & Health shares surge as Novo Nordisk drops GLP-1 lawsuit Atlanta VA joins clinical 30 Day supply:1 Box collection_bundles

Atlanta VA joins clinical trial studying GLP-1 drugs for alcohol use disorder – 95.5 WSB

Less clear is the extent to which GLP-1 changes are responsible for T2DM remission

collection_bundles

30 Day supply:1 Box

Drugs ORAL HYPOGLYCEMICS: : glyburide, glipizide, glimepiride Sulfonylureas : repaglinide, nateglinide Glinides : metformin Biguanide : acarbose, miglitol α-Glucosidase Inhibitors Thiazolidinediones or : pioglitazone, rosiglitazone Glitazones 1) : bromocriptine Dopamine agonist : canagliflozin, dapagliflozin, empagliflozin SGLT-2 Inhibitors : sitagliptin, saxagliptin, linagliptin, alogliptin DPP-IV Inhibitors INJECTIBLE HYPOGLYCEMICS : : exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide GLP-1 Agonists : pramlintide Amylin Analog BILE ACID SEQUESTRANTS: colesevelam INSULINS: PRANDIAL: : lispro, aspart, glulisine, inhaled Rapid acting : regular crystalline zinc Short-acting BASAL: : NPH (or Isophane) Intermediate acting : glargine, detemir Long acting : degludec Ultra-long acting INSULIN + GLP1 COMBINATIONS: glargine + lixisenatide (Soliqua ®) degludec + liraglutide (Xultophy ®) GOALS OF THERAPY Figure X